EGFR and non-small cell lung carcinoma: Several of them are considered actionable, and targeted therapy of molecular subtypes, such as tumors with an EGFR mutation and ALK rearrangements, have become the standard of therapy for advanced NSCLC, and targeted therapies for other driver mutations such as KRAS are being evaluated in clinical trials [72,73].